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Glomerular filtration rate in 
patients with atrial fibrillation and 
1-year outcomes
Giuseppe Boriani1,2, Cécile Laroche3, Igor Diemberger2, Mircea Ioachim Popescu4, 
Lars Hvilsted Rasmussen5, Lucian Petrescu6, Harry J. G. M. Crijns7, Luigi Tavazzi3,8, 
Aldo P. Maggioni3,9 & Gregory Y. H. Lip10
We assessed 1-year outcomes in patients with atrial fibrillation enrolled in the EurObservational 
Research Programme AF General Pilot Registry (EORP-AF), in relation to kidney function, as assessed 
by glomerular filtration rate (eGFR). In a cohort of 2398 patients (median age 69 years; 61% male), 
eGFR (ml/min/1.73 m2) calculated using the CKD-EPI formula was ≥80 in 35.1%, 50–79 in 47.2%, 
30–49 in 13.9% and <30 in 3.7% of patients. In a logistic regression analysis, eGFR category was an 
independent predictor of stroke/TIA or death, with elevated odds ratios associated with severe to mild 
renal impairment, ie. eGFR < 30 ml/min/1.73 m2 [OR 3.641, 95% CI 1.572–8.433, p < 0.0001], 30–49 ml/
min/1.73 m2 [OR 3.303, 95% CI 1.740–6.270, p = 0.0026] or 50–79 ml/min/1.73 m2 [OR 2.094, 95% CI 
1.194–3.672, p = 0.0003]. The discriminant capability for the risk of death was tested among various 
eGFR calculation algorithms: the best was the Cockcroft-Gault equation adjusted for BSA, followed 
by Cockcroft-Gault equation, and CKD-EPI equation, while the worst was the MDRD equation. In 
conclusion in this prospective observational registry, renal function was a major determinant of adverse 
outcomes at 1 year, and even mild or moderate renal impairments were associated with an increased 
risk of stroke/TIA/death.
Atrial fibrillation (AF) is the most common sustained arrhythmia, and its incidence and prevalence are increas-
ing worldwide1. Given its close association with age and various comorbidities, AF is commonly associated with 
impairment in renal function, of various degrees2.
AF is associated with an increased risk of stroke and thromboembolic events and risk stratification is essential 
for appropriate decision making with regard to anticoagulants3,4. There is growing interest on assessing renal 
function in patients with AF since compromise of renal function has major implications with regard to the risk of 
stroke and bleeding5. Indeed, a precise estimate of renal function is necessary in patients with non-valvular AF6,7 
who are candidates for treatment with the non vitamin K antagonist oral anticoagulants (NOACs)8.
Chronic kidney disease (CKD) is defined as the presence of kidney abnormalities, which can involve its 
structure and/or its function, for a period longer than 3 months, and glomerular filtration rate (GFR) is widely 
accepted as the best overall index of kidney function2. The GFR can be estimated from the serum creatinine 
using a number of different equations to give an estimated GFR (eGFR)2,9. Clinical Practice Guidelines delivered 
by KDIGO (Kidney Disease: Improving Global Outcomes) group for the evaluation and management of CKD 
recommended, in 2012, use of the CKD EPI equation for estimation of eGFR, on the basis of standardized serum 
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creatinine, and for staging of kidney function impairment2,9. This recommendation is not concordant with the 
advice to use Cockcroft-Gault equation for evaluating kidney function for the prescription of NOACs in cardi-
ology practice8.
The objective of this report from the EURObservational Research Programme – Atrial Fibrillation (EORP-AF) 
General Pilot Registry was to investigate the baseline characteristics and the outcomes at 1 year follow-up of pro-
spectively enrolled AF patients presenting to cardiologists, in relation to kidney function, as assessed by different 
equations for estimated glomerular filtration rate (eGFR) and 1-year outcomes, in terms of stroke and mortality in 
European AF patients followed by cardiologists. The analysis had also the aim to assess the concordance between 
the different equations proposed for estimating GFR and the potential differences in terms of outcome prediction.
The EORP-AF General Pilot Registry10–15 is a multicenter European registry which enrolled consecutive 
in- and out-patients presenting with documented AF to cardiologists, in participating centres from 9 European 
countries and includes patients with both valvular and non valvular AF with no exclusion criteria on the basis 
of co-morbidities such as renal or hepatic impairment. An additional objective of our analysis was to compare 4 
different equations of common clinical use for calculating eGFR with regard to concordance in estimate of kidney 
function and in terms of outcome prediction.
Methods
The methods and baseline data from the EORP-AF pilot general registry have previously been published8. The 
registry was commenced in early 2012. One-year follow-up phase (‘pilot phase’ or Phase 1) data were focused 
on patients from 9 countries (for a broad representation of European Society of Cardiology member countries) 
recruited into this database13.
In brief, the registry population comprised consecutive in- and out-patients presenting with AF to cardiol-
ogists, enrolled in 67 centres in 9 countries10–15. Consecutive patients were screened at the time of their pres-
entation to a cardiologist (hospital or medical centre), and potential patients were approached to obtain written 
informed consent according to local rules. The protocol of EORP AF was initially approved by the European 
Society of Cardiology (Sophia Antipolis, France) and then by the Institutional Review Boards, at a national or 
local level, according to country regulations. The research was performed in accordance with the ethical standards 
laid down in the 1964 Declaration of Helsinki and its later amendments. Enrollment required ECG-confirmed 
diagnosis of AF, with a qualifying episode of AF documented in the 12 months prior to enrollment. Stroke risk 
was categorised using the CHA2DS2-VASc score10–15, whilst bleeding risk was categorised using the HAS-BLED 
score10–12.
In this registry, parameters collected at enrollment included history of CKD, serum creatinine, body weight 
and the other parameters that permitted us to calculate eGFR according to the CKD Epidemiology Collaboration 
(CKD-EPI) equation, MDRD equation, Cockcroft-Gault equation, and BSA adjusted- Cockcroft-Gault equa-
tion2 (Table w1, web only appendix). Patients were classified on the basis of eGFR in 4 groups, corresponding to 
eGFR ≥ 80 ml/min/1.73 m2, between 50 and 79 ml/min/1.73 m2, between 30 and 49 ml/min/1.73 m2 and < 30 ml/
min/1.73 m2, respectively. The choice of the cuf-offs was in line with the cut-off commonly used for prescribing 
the appropriate dose of NOACs8. For the main analysis, patient classification according to eGFR calculated with 
CKD-EPI equation was used.
Outcomes were recorded for all cause mortality, cardiovascular death, thromboembolism (TE) and bleeding. 
TE refers to stroke, transient ischaemic attack (TIA), acute coronary syndrome (ACS), coronary intervention, car-
diac arrest, peripheral embolism and pulmonary embolism – each of these were as recorded by the investigator, 
in this ‘real world’ observational registry.
Statistical analyses. Univariate analysis was applied to both continuous and categorical variables. 
Continuous variables were reported as mean ± SD and/or as median and Interquartile Range (IQR), as appropri-
ate. Among-group comparisons were made using a non-parametric test (Kruskal-Wallis test). Categorical vari-
ables were reported as percentages. Among-group comparisons were made using a Chi-square test or a Fisher’s 
exact test if any expected cell count was less than five.
The association between eGFR and stroke/TIA or death at 1 year was analysed by logistic models. Odds ratios 
of eGFR with CKD-EPI equation were obtained with different models.
The first model included age and sex. The second model included age, sex and co-morbidities like coronary 
artery disease, chronic heart failure, previous stroke, previous TIA, ischaemic thrombo-embolic complications, 
haemorrhagic events and malignancy. At the second model, were added in the third model other potential con-
founding factors (variables with p < 0.10 in univariate, except those with a high number of missing data). And 
finally, among the last confounding factors a stepwise multiple logistic regression was used to keep only the signif-
icant variables. A significance level of 0.05 is required to allow a variable into the model (SLENTRY = 0.05) and a 
significance level of 0.05 is required for a variable to stay in the model (SLSTAY = 0.05). No interaction was tested. 
Hosmer and Lemeshow Goodness-of-Fit test was used to verify that the model was optimal.
Plots of the Kaplan-Meier curves for time to all-cause death in relation to eGFR subgroup were performed. 
The survival distributions have been compared using the log-rank test. Odds ratios [95% confidence intervals 
(CI)] comparing the categories of eGFR were derived from a logistic model.
Weighted Cohen’s kappa coefficient16 was used to assess the agreement in classification of patients in the dif-
ferent categories of eGFR (≥ 80 ml/min, between 50 and 79 ml/min, between 30 and 49 ml/min and < 30 ml/min) 
with the 4 different equations used for eGFR.
The relationship between eGFR categories and death prediction was evaluated through the AUCs of the ROC 
curves and ROC curves were then compared according to De Long, De Long and Clarke-Pearson method17.
A two-sided p value of < 0.05 was considered as statistically significant. All analyses were performed using 
SAS statistical software version 9.3 (SAS Institute, Inc., Cary, NC, USA).
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Results
A total of 2398 patients were evaluated in the present analysis, on the basis of availability of baseline data for cal-
culating eGFR, as well as availability of 1-year follow-up data or at least information on vital status at 1 year. This 
population of 2398 patients corresponds to 90.8% of the 2642 subjects with follow-up data. The distribution of 
patient population according to eGFR calculated with CKD-EPI equation is shown in Fig. 1. Of the study cohort, 
47.2% had mild renal impairment, and 17.6% had moderate-severe renal impairment.
Clinical characteristics associated with different categories of eGFR. The clinical characteristics 
of enrolled patients according to kidney function, as expressed by eGFR calculated with CKD-EPI, are shown 
in Table 1. There was a higher prevalence of elderly subjects, heart failure, valvular alterations, diabetes mellitus, 
hypertension and peripheral artery disease in the lower eGFR groups. Despite this, AF was more frequently 
asymptomatic (EHRA score I) in patients with severely compromised eGFR.
With regard to thrombotic risk, a history of ischaemic thrombo-embolic complications but not history of 
prior stroke, was more common in patients with more severely compromised eGFR reflecting the higher mean 
CHADS2 and CHA2DS2VASc scores. A history of hemorrhagic events, but not major bleeding per se, was more 
commonly found in patients with severely compromised eGFR and this was associated with higher HAS BLED 
scores (Table 1).
Prescribed interventions and medications. Interventions and medications at discharge/after consulta-
tion according to stages of renal function are shown in Table 2. There was more use of a rate control strategy in 
patients with progressively worse renal function. Overall use of antithrombotic drugs differed according to eGFR, 
with significantly lower prescription at discharge of oral anticoagulants (Table 2). Among AF patients with eGFR 
< 30 ml/min/1.73 m2 around 30% did not receive oral anticoagulants.
Outcomes at 1-year follow up and relationships with eGFR. Outcomes at 1-year follow up accord-
ing to stages of renal function (eGFR with CKD-EPI equation) are shown in Table 3. A progressive increase in 
the rate of adverse events observed at 1-yr follow up was found, mainly related to a steep increase in all-cause 
death in subgroups of patients belonging to categories with lower eGFR. For all-cause death and for the com-
posite end-point of ‘stroke/TIA/death’ the event rate at 1-year was almost 10-fold higher in patients with eGFR 
below 30 ml/min/1.73 m2, as compared to patients with eGFR above 80 ml/min/1.73 m2. Readmissions to hospi-
tal for cardiac reasons was also common (approximately one third of patients) with limited differences among 
eGFR subgroups, while readmission for non cardiac reasons was more common when renal function was more 
compromised.
In order to assess the potential impact of confounding factors on the relationship between eGFR and outcome, 
different models were considered with variable adjustments. The evolution of odds ratio for from crude models 
to fully adjusted models is reported in Table 4. As shown, the impact of confounding factors changes the values of 
odds ratio, but the odds of CKD stages still remains significant in all models.
Kaplan Meier curves of freedom from all-cause death according to different categories of renal function 
(eGFR with CKD-EPI equation) are shown in Fig. 2. Survival was significantly worse with eGFR below 30 ml/min 
(Log rank chi-square = 144.88, p < 0.0001).
eGFR with MDRD, Cockcroft-Gault and adjusted Cockcroft-Gault equations and outcomes. In 
Table 5 we show other calculations of eGFR using equations based on serum creatinine, and used in clinical 
practice, that is, MDRD, Cockcroft-Gault, Cockcroft-Gault adjusted for BSA. As expected, some differences were 
found in the number of patients allocated to each category of eGFR, according to the different formulas.
Figure 1. Distribution of patient population according to eGFR calculated with CKD-EPI equation. 
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All
CKD-EPI ≥80 ml/
min/1.73 m2
CKD-EPI 50–79 ml/
min/1.73 m2
CKD-EPI 30–49 
ml/min/1.73 m2
CKD-EPI <30 ml/
min/1.73 m2 P value
No. of patients 2398 842 1133 334 89
Demographics
Age in years Median (IQR) 69 (62–77) 64 (56–71) 71 (64–78) 76 (69–82) 76 (71–83) < 0.0001
Age  > = 75 yrs (%) 32.7 15.8 35.7 57.5 60.7 < 0.0001
Age > 65 yrs (%) 63.3 43.3 70.1 85.0 85.4 < 0.0001
Female gender (%) 39.3 30.5 41.9 50.9 46.1 < 0.0001
AF type (%)
 First detected 30.3 28.5 30.7 31.3 39.8 0.0001
 Paroxysmal 26.5 31.2 26.0 19.5 14.8
 Persistent 27.0 26.3 27.2 30.0 20.5
 Permanent 16.1 14.0 16.1 19.2 25.0
Concomitant disease (%)
 Lone AF 4.1 7.8 2.7 0.3 0 < 0.0001
 Coronary artery disease 35.7 26.1 38.5 47.8 46.3 < 0.0001
 Myocardial infarction 44.6 40.3 41.0 55.6 63.2 0.0012
 PTCA/CABG 46.8 44.8 45.8 50.0 55.3 0.5372
 Stable angina 36.3 37.8 36.6 34.7 31.6 0.8641
 Chronic heart failure 46.2 34.7 46.9 64.5 76.4 < 0.0001
  of whom NYHA III/IV 43.4 39.9 39.8 51.4 60.3 0.0005
 Valvular heart disease 61.2 51.4 62.5 77.0 78.8 < 0.0001
 Dilated cardiomyopathy 12.1 12.3 11.0 12.8 20.7 0.0559
 Hypertrophic cardiomyopathy 4.1 4.0 4.2 3.3 5.7 0.7655
 Restrictive cardiomyopathy 0.6 0.4 0.5 1.5 1.1 0.0972[* ]
 Hypertensive cardiomyopathy 19.8 18.2 20.0 22.7 20.7 0.3794
 Other cardiac disease 9.0 9.4 7.8 9.7 17.9 0.0156
Chronic obstructive pulmonary disease 12.0 10.8 10.7 18.8 13.8 0.0005
Hyperthyroidism 3.0 4.1 2.5 1.9 2.4 0.1413
Hypothyroidism 7.2 4.1 8.3 8.5 17.6 < 0.0001
Chronic kidney disease 13.7 1.0 8.0 45.0 92.0 < 0.0001
Peripheral vascular disease 12.2 8.8 11.2 18.9 32.6 < 0.0001
Cardiovascular risk factors (%)
 Diabetes 21.3 16.0 20.9 31.6 39.5 < 0.0001
 Hypertension 71.2 62.5 73.4 80.7 91.0 < 0.0001
 Current smoker 11.3 16.2 9.2 8.4 3.4 < 0.0001
 Hypercholesterolaemia 49.1 41.9 52.0 54.9 58.0 < 0.0001
 Alcohol > = 2–3/day 8.9 11.6 8.5 4.4 4.8 0.0008
Physical activity (%)
 None 38.2 30.0 37.7 53.7 62.8 < 0.0001
 Occasional 35.4 35.5 36.1 35.1 25.6
 Regular 21.7 28.1 21.5 9.9 9.3
 Intense 4.7 6.4 4.6 1.3 2.3
Co-morbidities (%)
Ischaemic thrombo-embolic complications 12.9 10.3 12.2 19.6 22.1 < 0.0001
Previous stroke 6.3 5.6 6.1 7.5 9.1 0.4364
Previous Transient Ischaemic Attack 3.9 3.2 3.3 6.9 6.8 0.0071
Haemorrhagic events 6.3 3.8 6.4 7.9 23.9 < 0.0001
Haemorrhagic stroke 4.6 3.1 5.6 3.8 4.8 > 0.999[* ]
Major bleeding 25.8 21.9 26.4 23.1 33.3 0.8029
Malignancy 5.5 4.0 6.1 6.5 7.1 0.1399
Main reason for admission/consultation (%)
 Atrial fibrillation 60.2 70.4 60.8 40.7 28.1 < 0.0001
 Acute myocardial infarction 4.4 2.9 4.8 7.5 3.4
 Valvular heart disease 3.4 2.1 3.8 5.1 3.4
 Hypertension 1.1 0.8 1.2 1.2 2.2
 Heart failure 17.1 11.9 15.6 29.0 41.6
Continued
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Using Cohen’s weighted K test for the concordance of attribution to each class of eGFR, we found agreement 
between the categorisations based on Cockcroft-Gault and Cockcroft-Gault adjusted equations, and those based 
on either CKD-EPI or MDRD equations were moderate to substantial (weighted K coefficients between 0.5755 
and 0.6404)16. Agreement between attributions based on CKD-EPI and MDRD was high and could be interpreted 
as “almost perfect agreement” (weighted K coefficient of 0.8918)16.
Kaplan Meier curves of freedom form all-cause death according to different categories of renal function, by 
calculating eGFR with MDRD, Cockcroft-Gault and Cockcroft-Gault adjusted for BSA equations are shown in 
the Supplementary web-only material (Figures w1, w2, w3). Irrespective of eGFR equation used, survival at 1 
year significantly differed according to eGFR categorisation. According to AUCs of the ROC curves, the best 
discriminant capability for death prediction according to eGFR categories was found for the Cockcroft-Gault 
equation adjusted for BSA (p < 0.0001 vs. MDRD equation and p = 0.0238 vs. CKD-EPI equation), followed by 
Cockcroft-Gault equation (p = 0.0002 vs. MDRD equation and p = 0.0676 vs. CKD-EPI equation), and CKD-EPI 
equation (p = 0.0023), while the worst was found for the MDRD equation (Fig. 3). No statistically significant 
difference was found between Cockcroft-Gault equation and the same equation adjusted for BSA (p = 0.9205).
Discussion
We found that in a group of patients with AF presenting to cardiologists across Europe evaluation of renal func-
tion with eGFR has important implications with regard to 1-year outcome (all-cause death or the combined 
end-point Stroke/TIA/death). Our principal findings indicate that only around 35% of patients have a normal 
eGFR and that AF is more frequently asymptomatic when it occurs in patients with severely compromised eGFR. 
Second, with regard to outcomes at 1-year follow up, we found that lower eGFR categories are associated with a 
steep increase in all-cause death, and with more hospital readmission for non cardiac reasons. Indeed, a reduced 
eGFR category appears to be a strong independent predictor of the end point of stroke/TIA or death and even 
mild or moderate impairments in renal function are associated with a significantly increased risk. Third, the con-
cordance between the different equations for estimating GFR was variable, and the best discriminant capability 
for the risk of death was found for the Cockcroft-Gault equation adjusted for BSA, followed by Cockcroft-Gault 
equation, and CKD-EPI equation, while the MDRD equation had the worst performance.
EORP-AF is a “real world” cardiology registry exploring all the spectrum of patients with AF presenting to 
cardiologists, with no exclusions due to characterization of AF as “valvular” or “non valvular”, extent of renal or 
hepatic dysfunction, age, malignancy or other co-morbidities10–15. Only around one third of the patients enrolled 
in EORP-AF had a normal eGFR (i.e. > 80 ml/min/1.73 m2) and therefore the finding that any category of eGFR 
below this normal value is associated with a worse outcome has clinical implications applicable to a large propor-
tion of AF patients.
In our study, significant differences in outcome at 1 year were found between different categories of renal func-
tion with regard to all-cause death and the combined end-point of stroke/TIA/death, while limited differences 
were found in the occurrence of stroke. The percentage of patients treated with oral anticoagulants, according 
to guidelines was relatively high (around 83–84%), with the only exception seen in patients with eGFR < 30 ml/
min/1.73 m2, where the use of oral anticoagulants dropped below 70%. The overall high use of anticoagulants 
may explain the relatively low incidence of strokes in a 1-year follow up period. As shown by Marijon et al. with 
regard to patients with non-valvular AF, the majority of deaths that occur in a contemporary anticoagulated AF 
population are not related to stroke, which per se only accounted for 7% of the cases of deaths observed18.
All
CKD-EPI ≥80 ml/
min/1.73 m2
CKD-EPI 50–79 ml/
min/1.73 m2
CKD-EPI 30–49 
ml/min/1.73 m2
CKD-EPI <30 ml/
min/1.73 m2 P value
 Other coronary artery disease 4.2 4.2 4.7 3.6 1.1
 Other cardiac 6.9 5.7 6.3 10.8 12.4
 Other non-cardiac reason 2.6 2.0 2.8 2.1 7.9
Symptoms
 EHRA I 40.2 34.9 40.7 47.3 57.3 < 0.0001
 EHRA II 30.9 34.8 30.6 25.1 18.0
 EHRA III–IV 28.9 30.3 28.7 27.5 24.7
CHADS2 score
 Mean score ± SD 1.93 ± 1.27 1.47 ± 1.17 1.97 ± 1.20 2.64 ± 1.24 2.99 ± 1.10 < 0.0001
 Two or more 60.3 44.1 62.8 84.4 92.1
CHA2DS2- VASc score
 Mean score ± SD 3.25 ± 1.80 2.43 ± 1.67 3.36 ± 1.65 4.47 ± 1.65 4.87 ± 1.42 < 0.0001
 Two or more 81.6 66.5 87.1 96.4 98.9
HAS-BLED score
 Mean score ±  SD 1.37 ± 1.08 0.95 ± 0.96 1.39 ± 0.97 2.00 ± 1.06 2.79 ± 1.07 < 0.0001
 Two or more 41.1 24.9 41.7 66.8 91.0
Table 1.  Patient characteristics at enrollment according to stages of renal function (eGFR with CKD-EPI 
equation). Kruskal-Wallis test is used for quantitative data. Chi-2 or Fisher exact test [* ] is used for binary 
variables. For qualitative variables with more than 2 possibilities, the Monte Carlo estimates of the exact 
p-values are used. IQR, interquartile range.
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In EORP-AF, hospitalizations for non cardiac causes markedly increased in relation to decreased renal func-
tion and this finding, related to the frequent association between CKD and other co-morbidities, such as hyper-
tension, coronary disease and diabetes mellitus, has important implications in terms of organization of health 
care (need for a multidisciplinary approach) and cost of care2,19.
All
CKD-EPI ≥80 ml/
min/1.73 m2
CKD-EPI 50–79 ml/
min/1.73 m2
CKD-EPI 30–49 ml/
min/1.73 m2
CKD-EPI <30 ml/
min/1.73 m2 P value
No. of patients 2398 842 1133 334 89
Management Strategy (%)
 Rate control 38.4 33.4 38.5 45.8 56.2 < 0.0001
 Rate and rhythm control 44.5 48.3 44.3 40.1 25.8
 Rhythm control only 13.3 15.0 13.6 8.1 12.4
 Observation 3.9 3.3 3.6 6.0 5.6
Interventions (%)
(on inpatients only) 1647 570 762 250 65
 Pharmacological cardioversion 29.2 33.0 28.9 25.3 15.6 0.0095
 Electrical cardioversion 24.2 25.3 25.5 21.5 9.4 0.0220
 Catheter ablation 9.6 15.9 8.3 2.0 0 < 0.0001
 Pacemaker implantation 4.2 3.5 5.0 3.2 4.6 0.4771
 ICD Implantation 1.0 0.9 0.7 2.4 1.5 0.1020[* ]
 Surgical therapy of AF 0.3 0.5 0.3 0 0 0.6601[* ]
Antithrombotic treatments (%)
 None 4.0 6.4 2.7 2.7 2.2 0.0002
 Antiplatelets 34.3 29.7 35.3 41.3 39.3 0.0009
 Oral anticoagulant 81.4 80.0 82.9 82.6 69.7 0.0104
  Vitamin K antagonists 90.4 90.8 88.7 93.5 98.4 0.0127
  NOAC 9.7 9.4 11.3 6.5 1.6 0.0134
Oral anticoagulant if indicated* * 83.0 82.8 84.3 83.1 69.7 0.0058
 of whom Vit K antagonists 90.7 91.2 88.9 93.5 98.4 0.0153
 of whom NOAC 9.4 8.9 11.1 6.5 1.6 0.0166
Antiarrhythmic drugs (%)
 At least one 35.4 35.8 37.0 32.1 24.7 0.0633
 Amiodarone 21.2 19.4 21.5 24.9 21.3 0.2124
Beta-blockers 70.7 68.4 70.6 76.6 71.9 0.0483
Digoxin 20.1 17.7 21.4 22.5 18.0 0.1372
ACE inhibitors 44.2 41.1 48.2 42.9 27.0 < 0.0001
ARBs 21.5 18.8 22.7 26.7 13.5 0.0039
Diuretics 52.7 39.4 54.5 72.5 80.9 < 0.0001
Aldosterone blockers 25.5 19.4 26.0 38.6 27.3 < 0.0001
Table 2.  Prescribed interventions and medications at discharge/after consultation according to stages of 
renal function (eGFR with CKD-EPI equation). NOAC, Non-VKA Oral AntiCoagulant. ACE, angiotensin 
converting enzyme. ARB, angiotensin receptor blockers. if indicated* * , CHA2DS2-VASc ≥ 2 or pharmacological 
cardioversion planned. * Chi-2 or Fisher exact test used for binary variables.
All
CKD-EPI ≥80 ml/
min/1.73 m2
CKD-EPI 50–79 ml/
min/1.73 m2
CKD-EPI 30–49 ml/
min/1.73 m2
CKD-EPI <30 ml/
min/1.73 m2 P-value
No. of patients 2398 842 1133 334 89
Events n(%)
 Stroke/TIA/death 178 (7.9%) 22 (2.8%) 73 (7.0%) 58 (18.5%) 25 (28.7%) < 0.0001
 All cause death 156 (6.5%) 19 (2.3%) 60 (5.3%) 53 (15.9%) 24 (27.0%) < 0.0001
 Stroke/TIA 22 (1.1%) 3 (0.4%) 13 (1.3%) 5 (1.9%) 1 (1.6%) 0.0509[* ]
 Bleeding 23 (1.1%) 6 (0.8%) 10 (1.0%) 6 (2.3%) 1 (1.6%) 0.1598[* ]
 Re-admission for cardiac reason 592 (28.6%) 196 (25.5%) 287 (29.4%) 91 (34.9%) 18 (29.5%) 0.0283
 Re-admission for non cardiac reason 268 (12.8%) 84 (10.8%) 125 (12.6%) 40 (15.4%) 19 (30.6%) < 0.0001
Table 3. Outcome in terms of adverse events at 1-year follow up according to stages of renal function 
(eGFR with CKD-EPI equation). Any TE = Stroke, TIA, ACS, Coronary intervention, cardiac arrest, 
peripheral embolism and pulmonary embolism. * Fisher exact test used for binary variables.
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Indeed, even mild to moderate reduction of eGFR have an impact on patients outcome in terms of increased 
risk of the combined end-point corresponding to TIA/stroke or death at 1 year. Of note, the increase in risk 
related to renal function can be more appropriately appreciated by considering allocation to categories of eGFR, 
rather than by considering more generic information such as “history of CKD”.
Our findings emphasise that assessment of eGFR, in daily practice should be done not only for calculating 
the appropriate dosing of drugs eliminated by the kidney, such as NOACs, but also for identifying those patients 
who have a worse prognosis and require more strict clinical surveillance. Detection and treatment of associ-
ated conditions like uncontrolled hypertension, diabetes or significant coronary disease are mandatory, as well 
as detection of (micro)albuminuria and assessment by a nephrologist to prevent further deterioration of renal 
function. Previous registries that investigated the outcome of patients with non valvular AF, including the ATRIA 
study20 and the Loire Valley Atrial Fibrillation Project21 did not analyse differences in outcome above a value of 
eGFR ≥ 60 ml. Our study provides the clinically important information that the risk of death or TIA/stroke/or 
death at 1 year is elevated even in patients in whom renal function is considered only slightly decreased, i.e. the 
risk is two-fold for patients with eGFR calculated with CKD-EPI formula between 50 and 79, as compared to 
patients with eGFR ≥ 80 ml/min/1.73 m2.
In clinical practice, many equations have been proposed for calculating eGFR on the basis of serum creati-
nine2,9, but it is unclear what formula is more commonly used or should be used. The KDIGO document recom-
mends use of the CKD-EPI equation9, while randomized trials that validated NOACs versus warfarin used the 
Cockcroft-Gault equation for dosing NOACs through eGFR2,8,22 and many laboratories report eGFR calculated 
with MDRD formula anytime serum creatinine is measured. In general, as already reported2, the clinician should 
remain aware of caveats for any estimating equation.
The MDRD23 equation uses 4 variables (age, gender, serum creatinine and ethnicity) to calculate eGFR and is 
widely used, especially in routine reports by many laboratories. The CKD-EPI equation24, which uses the same 
Model
eGFR CKD-EPI <30 vs ≥80 
ml/min/1.73 m2
eGFR CKD-EPI 30–49 vs ≥80 
ml/min/1.73 m2
eGFR CKD-EPI 50–79 vs ≥80 
ml/min/1.73 m2
Overall 
Pr > ChiSq
Model 1 (a) 7.955 [4.104; 15.418] p < 0.0001 4.622 [2.680; 7.972] p < 0.0001 1.883 [1.142; 3.105] p = 0.0132 p < 0.0001
Model 2 (b) 6.834 [3.248; 14.377] p < 0.0001 4.185 [2.260; 7.749] p < 0.0001 1.912 [1.083; 3.376] p = 0.0255 p < 0.0001
Model 3(c) 5.616 [2.258; 13.971] P = 0.0002 4.135 [1.902; 8.991] P = 0.0003 2.247 [1.117; 4.520] p = 0.0231 P = 0.0004
Model 4 (d) 4.699 [2.113; 10.449] P = 0.0001 3.004 [1.551; 5.819] P = 0.0011 1.792 [0.978; 3.285] p = 0.0591 P = 0.0003
Table 4.  Evolution of odds ratio [95% Wald Confidence Limits] of eGFR with the outcome stroke/TIA or death 
at 1 year. (a) Model 1 includes age and sex. Hosmer and Lemeshow Goodness-of-Fit p-value = 0.2248. (b) Model 
2 includes age, sex and co-morbidities: coronary artery disease, chronic heart failure, previous stroke, previous 
TIA, ischaemic thrombo-embolic complications, haemorrhagic events and malignancy. Hosmer and Lemeshow 
Goodness-of-Fit p-value = 0.1183. (c) Model 3 is the model 2 with confounding factors significant (p < 0.1) in 
the univariate model, i.e. nation, setting, AF type, valvular heart disease, cardiomyopathy, other cardiac disease, 
COPD, peripheral vascular disease, diabetes, alcohol > = 2–3/day, physical activity, previous pharmacological 
cardioversion, electrical cardioversion, catheter ablation, EHRA symptoms - BMI - SBP - DBP - Management 
Strategy - Main reason for admission/consultation. Hosmer and Lemeshow Goodness-of-Fit p-value = 0.7486. 
(d) Model 4 is the model 2 with confounding factors significant (p < 0.1) in the univariate model and kept into 
the model with the stepwise procedure, i.e. nation, diabetes, physical activity and main reason for admission/
consultation. Hosmer and Lemeshow Goodness-of-Fit p-value = 0.6485.
Figure 2. Kaplan Meier curve of freedom from all-cause death according stages of renal function (eGFR 
with CKD-EPI equation). (Log rank chi-square = 144.88, p < 0.0001).
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4 variables as the MDRD, is becoming more widely adopted25, according to recommendations9, and appears 
to have greater accuracy and precision than the MDRD equation, with less bias at GFR > 60 ml/min/1.73 m2 26. 
The Cockcroft-Gault equation, proposed around 40 years ago27, has a series of bias in patients with a high body 
weight or BMI and its overall accuracy is lower than that of the two other formulas28. In this context, our analysis 
on the concordance in eGFR values and in allocation to different classes of renal dysfunction according to the 
different formulas used for eGRF, as done in our analysis, is of clinical value. While the discordance between 
MDRD, CKD-EPI and Cockcroft-Gault formulas was previously reported by Manzano-Fernandez et al.29 with 
regard to dosing of NOACs,no prior analysis has compared these formulas with regard to prognostic implications 
in AF patients. In our study, the concordance in allocation to eGFR categories was lower when considering the 
Cockcroft-Gault equation versus the other two equations, similarly to what found in patients with heart failure30.
With regard to the risk of death significant differences according to allocation to different eGFR categories 
were found. Even if the predicting capabilities may show some variations according to the equation used for 
eGFR calculation, the prediction of worse outcome in the presence of a low eGFR category is maintained for 
CKD-EPI  
(ml/min/1.73 m2)
MDRD  
(ml/min/1.73 m2)
Cockcroft-Gault  
(ml/min)
Cockcroft-Gault adjusted 
(ml/min/1.73 m2)
2398 patients 2398 patients 2398 patients 2398 patients
Number of patients (%) 
with eGFR ≥ 80 842 (35.1%) 902 (37.6%) 1076 (44.9%) 770 (32.1%)
Number of patients (%) 
with eGFR 50–79 1133 (47.2%) 1143 (47.7%) 879 (36.7%) 1117 (46.6%)
Number of patients (%) 
with eGFR 30–49 334 (13.9%) 285 (11.9%) 354 (14.8%) 411 (17.1%)
Number of patients (%) 
with eGFR < 30 89 (3.7%) 68 (2.8%) 89 (3.7%) 100 (4.2%)
Mean ± SD of eGFR 69.93 ± 21.19 73.77 ± 23.87 79.74 ± 33.77 70.41 ± 25.71
Weighted K coefficients (and 95% CI) and classes of renal function based on eGFR estimates
MDRD Cockcroft-Gault Cockcroft-Gault adjusted
CKD-EPI 0.8918 (0.8776–0.9061) 0.6242 (0.6000–0.6483) 0.7254 (0.7039–0.7469)
MDRD 0.5755 (0.5499–0.6012) 0.6404 (0.6164–0.6643)
Cockcroft-Gault 0.7654 (0.7460–0.7848)
Table 5.  Evaluation of eGFR with different equations (top panel) and concordance of attribution to each 
class of eGFR with Cohen’s weighted K test (bottom panel).
Figure 3. ROC curves and AUCs for death prediction according to eGFR categories with different 
equations for eGFR. 
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every specific eGFR formula adopted. Of note, in our study, the best discriminant capability for death at 1 year 
was found for the Cockcroft-Gault equation adjusted for BSA, suggesting that this should perhaps be the method 
of choice when using eGFR for predicting the risk of death.
Limitations. The patients were enrolled in EORP AF through cardiology clinics and therefore the study find-
ings cannot be generalized to patients treated by internists, or general practitioners. Albuminuria, which is an 
important component of assessment of kidney dysfunction was not evaluated, similarly to many other studies 
performed in the cardiology setting2,21. Finally, as in any observational study we cannot exclude the presence of 
some residual confounding, persisting despite adjustment for a series of variables, due to unmeasured factors, or 
binarily categorized factors.
Conclusions
In this one-year follow-up analysis of a registry of “real world” patients with AF followed by cardiologists, renal 
function was a major determinant of adverse outcomes, and even mild or moderate impairments in renal function 
were associated with an increased risk of stroke/TIA/death. The best discriminant capability for death according 
to eGFR categories was found for the Cockcroft-Gault equation adjusted for BSA.
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